Atrix Laboratories, Inc.
Pharmaceutical firm reports 53% increase in revenue due to Eligard sales
Published in Physician Law Weekly, September 1st, 2004
Total revenue increased 53% to $18.9 million in the second quarter of 2004 compared to $12.3 million for the same quarter in 2003. The revenue increase was due primarily to $9.9 million in sales and royalty revenue earned from the continued growth of the Eligard (leuprolide acetate for injectable suspension) prostate cancer products.
This represents a 42% increase in Eligard sales and royalty revenue compared to the first quarter of 2004.
Operating expenses in the second quarter of 2004 increased to...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Physician Law Weekly
Source: Physician Law Weekly (2004-09-01)
More Articles from Physician Law Weekly
- Abbott Laboratories
Government decides not to intervene and force down AIDS drug price - Archemix Corp.
Biopharmaceutical company names vice president of business development - Best Practices, LLC
Drug companies approach brand security issue head on, study shows - Business Update
Altria sees $25 million gain from accounting rule - Ciphergen Biosystems Inc.
Report published on biomarkers for early diagnosis of intra-amniotic infection - CytRx Corp.
RNAi company names Benjamin S. Levin general counsel - More from this issue of Physician Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
